Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment

Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of phosphoinositide 3-kinase (PI3K)/Akt inhibition using three AZD compounds in a NOD-SCID xenograft mouse model and Akt regulation in a panel of eight ovarian cancer cell line...

Full description

Bibliographic Details
Main Authors: Yi-Hui Wu, Yu-Fang Huang, Chien-Chin Chen, Chia-Yen Huang, Cheng-Yang Chou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Pharmacology
Subjects:
epithelial ovarian carcinoma
chemoresistance
PI3K inhibitor
Akt inhibitor
cisplatin
paclitaxel
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00206/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00206/full

Similar Items